Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLSE

Pulse Biosciences Inc

Apr 15 • 03:55PM ET

19.67

-0.45 -2.26 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: CUTR IRTC NVRO ITGR IART ANIK NEO MDXG STER TMDX

| Held by: VTI IWM VXF IWO VTWO SCHA VHT IWC ITOT ISMD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	74.03%	Shs Outstand	67.84M	Perf Week	3.17%
Market Cap	1.34B	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-0.25%	Shs Float	17.66M	Perf Month	-9.92%
Enterprise Value	1.26B	PEG	-	EPS next Q	-0.27	Inst Own	9.45%	Short Float	16.51%	Perf Quarter	38.98%
Income	-72.78M	P/S	3820.01	EPS this Y	-56.40%	Inst Trans	6.07%	Short Ratio	8.35	Perf Half Y	13.47%
Sales	0.35M	P/B	16.54	EPS next Y	-8.47%	ROA	-63.24%	Short Interest	2.92M	Perf YTD	43.23%
Book/sh	1.19	P/C	16.56	EPS next 5Y	-1.54%	ROE	-74.45%	52W High	26.30 -25.23%	Perf Year	15.47%
Cash/sh	1.19	P/FCF	-	EPS past 3/5Y	14.44% 12.82%	ROIC	-84.03%	52W Low	12.56 56.57%	Perf 3Y	240.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-20.63% -	Gross Margin	-358.29%	Volatility	7.36% 7.33%	Perf 5Y	-9.67%
Dividend TTM	-	EV/Sales	3610.87	EPS Y/Y TTM	-19.63%	Oper. Margin	-21982.57%	ATR (14)	1.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.51	Sales Y/Y TTM	-	Profit Margin	-20794.57%	RSI (14)	46.50	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.53	EPS Q/Q	17.67%	SMA20	-6.17%	Beta	1.70	Target Price	30.00
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	-4.62%	Rel Volume	0.44	Prev Close	20.12
Employees	116	LT Debt/Eq	0.07	Earnings	Feb 19 AMC	SMA200	17.22%	Avg Volume	349.34K	Price	19.67
IPO	May 18, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.98% 76.00%	Trades		Volume	152,811	Change	-2.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Initiated	Mizuho	Outperform	$25
Jul-07-25	Initiated	Oppenheimer	Outperform	$22
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Apr-10-26 12:12AM	Pulse Biosciences hires Liane Teplitsky as COO (MedTech Dive)
Apr-09-26 07:00AM	Pulse Biosciences Strengthens Executive Leadership Team (Business Wire)
Apr-07-26 07:00AM	Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation (Business Wire) -12.99%
Apr-02-26 04:05PM	Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-26 07:00AM	Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data (Business Wire)
07:00AM	Loading…
Mar-12-26 07:00AM	Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse Technology (Business Wire) +6.45%
Mar-09-26 07:00AM	Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation (Business Wire)
Mar-05-26 07:00AM	Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference (Business Wire)
Mar-04-26 07:00AM	Pulse Biosciences' nPulse Vybrance System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting (Business Wire)
Feb-20-26 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -14.59% -5.74%
08:30AM	Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
07:00AM	Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference (Business Wire)
12:02AM	Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Highlights: Innovations and Challenges in Focus (GuruFocus.com)
Feb-19-26 10:07PM	Pulse Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:45PM	Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results (Business Wire)
Feb-09-26 12:58PM	PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data (Zacks) +16.67%
09:18AM	What's Going With Pulse Biosciences Stock On Monday? (Benzinga)
Feb-06-26 01:58PM	Pulse Biosciences Heart Device Data Fuels Stock Surge (Benzinga) +51.57%
Feb-05-26 07:00PM	Pulse Biosciences Presents Late-Breaking Data from nPulse Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium (Business Wire) -9.40%
Feb-04-26 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 (Business Wire) +7.62%
Feb-03-26 07:00AM	Pulse Biosciences' nPulse Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium (Business Wire)
Jan-09-26 07:00AM	Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors (Business Wire)
Jan-06-26 07:00AM	Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium (Business Wire)
Dec-29-25 04:05PM	Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.12%
10:25AM	PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial (Zacks)
Dec-18-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation (Business Wire)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
Dec-09-25 07:00AM	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology (Business Wire)
04:05PM	Loading…
Nov-21-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-25 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
12:03AM	Pulse Biosciences Inc (PLSE) Q3 2025 Earnings Call Highlights: Regulatory Milestones and Early ... (GuruFocus.com)
Nov-05-25 06:15PM	Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results (Business Wire)
Oct-24-25 07:00AM	Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study (Business Wire)
Oct-22-25 04:05PM	Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025 (Business Wire)
Oct-16-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-13-25 08:14AM	Pulse Biosciences Unveils Promising First-in-Human Data for nPulse (Zacks)
Oct-10-25 07:00AM	Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire) -8.57%
Oct-07-25 07:00AM	Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire)
Oct-01-25 01:40PM	Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial (Insider Monkey)
Sep-17-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 12:24PM	Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study (Zacks)
Sep-10-25 07:00AM	Pulse Biosciences' nPulse Technology to be Featured at the American Thyroid Association 2025 Annual Meeting (Business Wire)
Sep-09-25 07:00AM	Pulse wins IDE approval; Galvanize pulls in $100M (MedTech Dive)
Sep-08-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation (Business Wire)
Sep-04-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 07:00AM	Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study (Business Wire)
Aug-27-25 12:25PM	PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment (Zacks) -6.27%
Aug-26-25 07:00AM	Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid (Business Wire)
Aug-13-25 03:12AM	Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: Navigating Increased Expenses ... (GuruFocus.com) +11.19%
Aug-12-25 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results (Business Wire)
Aug-01-25 07:00AM	Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025 (Business Wire)
Jul-16-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-23-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-25 03:41AM	Pulse Biosciences Inc (PLSE) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-08-25 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results (Business Wire)
May-06-25 04:05PM	Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference (Business Wire)
May-01-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting (Business Wire)
Apr-25-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.06%
Apr-24-25 04:05PM	Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 (Business Wire) +6.00%
Apr-23-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting (Business Wire)
Apr-10-25 01:00PM	Pulse Biosciences: Some Key Questions Remain Unanswered (Seeking Alpha)
10:36AM	Pulse Biosciences: Interesting Product, But No Revenue Stream (Seeking Alpha)
Mar-28-25 08:10AM	Q4 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.00%
03:03AM	Pulse Biosciences Inc (PLSE) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Mar-27-25 07:46PM	Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results (Business Wire)
Mar-26-25 04:05PM	Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference (Business Wire)
Mar-07-25 08:00AM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 (Business Wire)
Mar-04-25 08:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-25 04:05PM	Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-05-25 09:42AM	Pulse Biosciences names new CFO, continuing string of C-suite changes (MedTech Dive)
Feb-04-25 08:00AM	Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer (Business Wire) +14.84%
Jan-30-25 08:00AM	Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting (Business Wire)
Jan-21-25 01:03PM	Pulse Biosciences touts positive results from PFA early feasibility study (Medical Device Network) +11.16%
07:00AM	Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium (Business Wire)
Jan-13-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium (Business Wire)
Jan-10-25 08:00AM	Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer (Business Wire)
Jan-03-25 09:00AM	Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +10.34%
Dec-23-24 04:30PM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire) +5.34%
Dec-19-24 08:00AM	Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants (Business Wire)
Dec-17-24 08:00AM	Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery (Business Wire)
Oct-31-24 02:25PM	Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association (Business Wire)
01:58PM	Q3 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
05:01AM	Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-30-24 04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results (Business Wire)
04:02PM	Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology (Business Wire)
Oct-21-24 08:00AM	Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 (Business Wire)
Aug-21-24 07:55AM	Better Cotton Pakistan, PULSE to boost data transparency in cotton farming (Just Style) +13.76%
Aug-13-24 12:38PM	Q2 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +8.05%
Aug-12-24 04:05PM	Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results (Business Wire)
04:01PM	Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors (Business Wire)
Aug-09-24 06:32AM	Pulse Biosciences launches first-in-human pulsed field ablation trial (Medical Device Network)
Aug-08-24 08:00AM	Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System (Business Wire) +9.74%
Aug-01-24 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
Jul-29-24 04:05PM	Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 (Business Wire) -11.36% -5.95%
Jul-09-24 07:27AM	Pulse drops 510(k) plan for PFA device after FDA requests clinical data (MedTech Dive)

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Danahy Kevin Patrick	Chief Commercial Officer	Feb 18 '26	Option Exercise	1.53	5,000	7,650	48,298	Feb 23 08:55 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 18 '26	Sale	23.64	5,000	118,200	43,298	Feb 23 08:55 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 12 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 13 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 17 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 17 '26	Sale	23.63	20,000	472,600	43,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 13 '26	Sale	23.53	20,000	470,600	43,298	Feb 17 08:47 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 12 '26	Sale	23.37	20,000	467,400	43,298	Feb 17 08:47 PM
KEVIN DANAHY	Officer	Feb 12 '26	Proposed Sale	25.25	50,000	1,262,500		Feb 12 04:27 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 09 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 10 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 11 '26	Option Exercise	1.53	20,000	30,600	63,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 11 '26	Sale	25.20	20,000	504,000	43,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 10 '26	Sale	23.52	20,000	470,400	43,298	Feb 11 07:46 PM
Danahy Kevin Patrick	Chief Commercial Officer	Feb 09 '26	Sale	21.45	20,000	429,000	43,298	Feb 11 07:46 PM
KEVIN DANAHY	Officer	Feb 09 '26	Proposed Sale	20.75	75,000	1,556,250		Feb 09 04:30 PM
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Option Exercise	1.53	4,600	7,038	47,898	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Sale	18.53	4,600	85,238	43,298	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Option Exercise	1.53	20,000	30,600	63,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Option Exercise	1.53	400	612	43,698	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Sale	18.49	20,000	369,800	43,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Sale	18.48	400	7,392	43,298	Sep 22 09:24 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Option Exercise	4.00	181,534	726,136	284,406	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Sale	16.28	25,000	407,000	122,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Sale	16.21	20,000	324,200	122,872	Sep 18 08:44 PM
KEVIN DANAHY	Officer	Sep 18 '25	Proposed Sale	16.27	25,000	406,750		Sep 18 04:29 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Sale	15.77	25,000	394,250	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Sale	14.78	25,000	369,500	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Sale	14.32	25,000	358,000	122,872	Sep 15 09:09 PM
DUGGAN ROBERT W	Director	Sep 10 '25	Buy	14.66	34,659	508,101	47,551,200	Sep 12 08:14 PM
DARRIN UECKER	Director	Sep 11 '25	Proposed Sale	14.77	120,000	1,772,400		Sep 11 04:30 PM
UECKER DARRIN	Chief Technology Officer	Jun 12 '25	Sale	16.40	15,000	246,000	137,872	Jun 16 08:23 PM
UECKER DARRIN	Chief Technology Officer	Jun 13 '25	Sale	15.98	15,000	239,700	122,872	Jun 16 08:23 PM
DARRIN UECKER	Officer	Jun 13 '25	Proposed Sale	15.98	15,000	239,740		Jun 13 04:14 PM
DARRIN UECKER	Officer	Jun 12 '25	Proposed Sale	16.40	15,000	246,048		Jun 12 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLSE

Pulse Biosciences Inc

Upgrade your Finviz experience